Latest Soligenix Inc. (SNGX) Headlines
Soligenix to Present at 2014 World Vaccine Congress in Washington, DC
PR Newswire - Tue Mar 11, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that its Chief Scientific Officer, Robert N. Brey, PhD, will give a presentation on the "Development of Thermostable Subunit Vaccines" at the 2014 World Vaccine Congress - Biotech Showcase on Tuesday, March 25, 2014. The presentation will take place at 2:10 PM Eastern Daylight Time (EDT) at the Marriott Wardman Park Hotel in Washington, DC, where Dr. Brey will, in part, review the Company's achievements to date with its ThermoVax(TM) vaccine heat stabilization technology.
Soligenix Inc receives USD300,000 NIAID SBIR grant to support further evaluation of SGX943 for the treatment of melioidosis
M2 - Mon Feb 17, 6:00AM CST
Biopharmaceutical company Soligenix Inc (OTC BB:SNGX) reported on Friday the receipt of USD300,000 Small Business Innovation Research (SBIR) grant to support further preclinical development of SGX943 for the treatment for melioidosis.
Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
PR Newswire - Fri Feb 14, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support further preclinical development of SGX943 as a treatment for melioidosis. The award will provide Soligenix with approximately $300,000 over one year to conduct the studies in collaboration with Tulane University.
Soligenix to Present at the 16th Annual BIO CEO & Investor Conference in New York City
PR Newswire - Wed Feb 05, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 16th Annual BIO CEO Investor Conference in New York City, on Monday, February 10, 2014 at 3:00 PM Eastern Standard Time (EST). The presentation will take place in the Conrad room at the Waldorf Astoria.
B&B Music Lessons in the Mid-Atlantic Celebrates Ninth Anniversary
PR Newswire - Tue Feb 04, 7:30AM CST
B&B Music Lessons, based in Washington, D.C., is celebrating its ninth anniversary this March. Owners Brad Clements and Bhagwan Khalsa are pleased with the progress they've made since starting the business in 2005. The school currently has 65 teachers and 370 students, mostly age five to 15.
U.S. Chamber's Global IP Center Unveils 2014 International Intellectual Property Index
PR Newswire - Tue Jan 28, 11:01PM CST
Report Sheds Light on Progress, Deficiencies in 25 Countries' IP Environments, Including Select TPP Participants
Soligenix Inc awarded USD750,000 in non-dilutive financing from New Jersey's Technology Business Tax Certificate Transfer Program
M2 - Fri Jan 17, 10:43AM CST
Biopharmaceutical company Soligenix Inc (OTC BB:SNGX) reported on Thursday that it has received about USD750,000, net of transaction costs, in non-dilutive financing via the State of New Jersey's Technology Business Tax Certificate Transfer Program.
Soligenix Receives $750,000 in Non-Dilutive Financing from New Jersey's Technology Business Tax Certificate Transfer Program
PR Newswire - Thu Jan 16, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well a developing several biodefense vaccines and therapeutics, announced today that it has recently received approximately $750,000, net of transaction costs, in non-dilutive financing via the State of New Jersey's Technology Business Tax Certificate Transfer Program (the Program).
Soligenix Announces Positive One-Year High-Temperature Stability Results with ThermoVax(TM) Vaccine Heat Stabilization Technology
PR Newswire - Wed Jan 15, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today significant steps forward in the development of ThermoVax(TM), its proprietary vaccine thermostabilization platform technology. Recent studies have demonstrated the potential for heat-sensitive vaccines formulated using this technology to withstand temperatures exceeding 40 degrees Celsius (104 degrees Fahrenheit) for up to one year. The underlying work has been conducted with the Company's proprietary ricin toxin vaccine (RiVax(TM)) as part of a continuing program to evaluate the effectiveness of protein subunit vaccines to withstand extremes of temperature and other environmental stress conditions. These studies amplify and extend former evaluations that indicated retention of potency for at least six months at temperatures as high as 40 degrees Celsius, outside the range of typical vaccine storage conditions. The research and development of ThermoVax(TM) is currently being supported by a $9.4 million National Institute of Allergy and Infectious Disease (NIAID) grant to Soligenix for biodefense vaccines to prevent ricin toxin and anthrax exposure.
Soligenix to Present at the 2014 Biotech Showcase in San Francisco
PR Newswire - Thu Jan 09, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 2014 Biotech Showcase in San Francisco, California on Tuesday, January 14, 2014 at 11:00 AM Pacific Standard Time (PST). The presentation will take place on the third floor of the Parc 55 Wyndham Hotel.
Courseload Releases Courseload Engage Learning Application for Faculty and Students
PR Newswire - Tue Jan 07, 9:00AM CST
Courseload, an institutional solution for the delivery and use of eTextbooks and digital course materials in higher education, today announced the release of Courseload Engage (Engage), its next generation application designed to enhance engagement and collaboration between students and instructors.
Soligenix Appoints Richard Straube, MD, as Chief Medical Officer
PR Newswire - Mon Jan 06, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has appointed Richard Straube, MD, as its Senior Vice President and Chief Medical Officer. Dr. Straube is a board-certified pediatrician with clinical research experience in host-response modulation. He has had a long and distinguished career of more than 35 years in both academia and industry, most notably with Centocor, Ohmeda Pharmaceuticals, INO Therapeutics, and Stealth Peptides, Inc. Dr. Straube will lead Soligenix's clinical research with primary responsibility for the execution and completion of its multiple clinical programs, including its Phase 2 study in oral mucositis and its Phase 2/3 study in pediatric Crohn's disease.
Dai Telecom and Galooli Announce Cooperation
PR Newswire - Thu Dec 19, 3:00AM CST
Dai Telecom Ltd. and Galooli Ltd. today announced cooperation in the area of remote vehicle telematics. The cooperation centers on the integration of Dai Telecom's Roadstar advanced car phone with Galooli's remote performance monitoring platform - the ZON Control. This solution enables customers to use hands free smart phone capabilities in the car along with advanced remote tracking and fleet management solution, using neither extra hardware nor installation.
Soligenix Inc begins Phase 2 clinical trial of orBec for chronic GI GVHD under USD300,000 NCI grant
M2 - Tue Dec 03, 5:19AM CST
Biopharmaceutical company Soligenix Inc (OTC BB:SNGX) revealed on Monday the launch of a Phase 2, randomised, double-blind, placebo-controlled study evaluating orBec as a treatment for the gastrointestinal (GI) manifestations of chronic Graft-versus-Host disease (GVHD).
Soligenix Announces Initiation of a Phase 2 Clinical Trial of orBec® for the Treatment of Chronic GI GVHD
PR Newswire - Mon Dec 02, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec® (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal (GI) manifestations of chronic Graft-versus-Host disease (GVHD). The study is partially funded by the National Cancer Institute (NCI) which has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 2 clinical trial. The award provides Soligenix with approximately $300,000 over a two-year period.
Soligenix Announces Initial $600,000 Investment and up to $10.6 Million Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC
PR Newswire - Thu Nov 21, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it signed a stock purchase agreement with Lincoln Park Capital Fund, LLC (LPC) providing an initial investment in Soligenix of $600,000 and the availability of additional periodic investments up to $10.0 million over a 36 month term.
Soligenix Reports Third Quarter 2013 Financial Results, and Highlights Recent Accomplishments
PR Newswire - Tue Nov 12, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the quarter and nine months ended September 30, 2013.
Soligenix Submits NIAID Contract Proposal for Development of a Thermostable Ricin Vaccine
PR Newswire - Thu Oct 31, 6:15AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures (MCMs) where there remains an unmet medical need, announced today submission of a full contract proposal to the National Institute of Allergy and Infectious Diseases (NIAID), Division of Microbiology and Infectious Diseases. Successful award of the proposal would support a multi-year, multi-million dollar contract for the advanced development of RiVax(TM) as a vaccine MCM candidate for biodefense threats to protect the public.
Soligenix to Host Conference Call and Webcast Discussion on Oral Mucositis
PR Newswire - Mon Oct 28, 6:15AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet medical need, announced today that Christopher J. Schaber, PhD, President and Chief Executive Officer, Oreola Donini, PhD, Vice President of Preclinical Research and Development, and Stephen T. Sonis, DMD, DMSc, Clinical Professor of Oral Medicine at Harvard School of Dental Medicine, Senior Surgeon and Chief, Divisions of Oral Medicine at Brigham and Women's Hospital and the Dana-Farber Cancer Institute, and Chief Scientific Officer of Biomodels, LLC, as well as Scientific Advisory Board Member and Lead Advisor for the Soligenix Phase 2 clinical study of SGX942 for the treatment of oral mucositis in head and neck cancer, will participate in an expert call and webcast, entitled: Oral Mucositis - Advancing the Next Generation of Therapies.
Soligenix Inc appoints Marco Maria Brughera to board
M2 - Tue Oct 22, 6:05AM CDT
Biopharmaceutical company Soligenix Inc (OTC BB:SNGX) of Marco Maria Brughera, DVM, to its Board of Directors.
Soligenix to Present at 2014 World Vaccine Congress in Washington, DC
PR Newswire - Tue Mar 11, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that its Chief Scientific Officer, Robert N. Brey, PhD, will give a presentation on the "Development of Thermostable Subunit Vaccines" at the 2014 World Vaccine Congress - Biotech Showcase on Tuesday, March 25, 2014. The presentation will take place at 2:10 PM Eastern Daylight Time (EDT) at the Marriott Wardman Park Hotel in Washington, DC, where Dr. Brey will, in part, review the Company's achievements to date with its ThermoVax(TM) vaccine heat stabilization technology.
Soligenix Inc receives USD300,000 NIAID SBIR grant to support further evaluation of SGX943 for the treatment of melioidosis
M2 - Mon Feb 17, 6:00AM CST
Biopharmaceutical company Soligenix Inc (OTC BB:SNGX) reported on Friday the receipt of USD300,000 Small Business Innovation Research (SBIR) grant to support further preclinical development of SGX943 for the treatment for melioidosis.
Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
PR Newswire - Fri Feb 14, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support further preclinical development of SGX943 as a treatment for melioidosis. The award will provide Soligenix with approximately $300,000 over one year to conduct the studies in collaboration with Tulane University.
Soligenix to Present at the 16th Annual BIO CEO & Investor Conference in New York City
PR Newswire - Wed Feb 05, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 16th Annual BIO CEO Investor Conference in New York City, on Monday, February 10, 2014 at 3:00 PM Eastern Standard Time (EST). The presentation will take place in the Conrad room at the Waldorf Astoria.
B&B Music Lessons in the Mid-Atlantic Celebrates Ninth Anniversary
PR Newswire - Tue Feb 04, 7:30AM CST
B&B Music Lessons, based in Washington, D.C., is celebrating its ninth anniversary this March. Owners Brad Clements and Bhagwan Khalsa are pleased with the progress they've made since starting the business in 2005. The school currently has 65 teachers and 370 students, mostly age five to 15.
U.S. Chamber's Global IP Center Unveils 2014 International Intellectual Property Index
PR Newswire - Tue Jan 28, 11:01PM CST
Report Sheds Light on Progress, Deficiencies in 25 Countries' IP Environments, Including Select TPP Participants
Soligenix Inc awarded USD750,000 in non-dilutive financing from New Jersey's Technology Business Tax Certificate Transfer Program
M2 - Fri Jan 17, 10:43AM CST
Biopharmaceutical company Soligenix Inc (OTC BB:SNGX) reported on Thursday that it has received about USD750,000, net of transaction costs, in non-dilutive financing via the State of New Jersey's Technology Business Tax Certificate Transfer Program.
Soligenix Receives $750,000 in Non-Dilutive Financing from New Jersey's Technology Business Tax Certificate Transfer Program
PR Newswire - Thu Jan 16, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well a developing several biodefense vaccines and therapeutics, announced today that it has recently received approximately $750,000, net of transaction costs, in non-dilutive financing via the State of New Jersey's Technology Business Tax Certificate Transfer Program (the Program).
Soligenix Announces Positive One-Year High-Temperature Stability Results with ThermoVax(TM) Vaccine Heat Stabilization Technology
PR Newswire - Wed Jan 15, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today significant steps forward in the development of ThermoVax(TM), its proprietary vaccine thermostabilization platform technology. Recent studies have demonstrated the potential for heat-sensitive vaccines formulated using this technology to withstand temperatures exceeding 40 degrees Celsius (104 degrees Fahrenheit) for up to one year. The underlying work has been conducted with the Company's proprietary ricin toxin vaccine (RiVax(TM)) as part of a continuing program to evaluate the effectiveness of protein subunit vaccines to withstand extremes of temperature and other environmental stress conditions. These studies amplify and extend former evaluations that indicated retention of potency for at least six months at temperatures as high as 40 degrees Celsius, outside the range of typical vaccine storage conditions. The research and development of ThermoVax(TM) is currently being supported by a $9.4 million National Institute of Allergy and Infectious Disease (NIAID) grant to Soligenix for biodefense vaccines to prevent ricin toxin and anthrax exposure.
Soligenix to Present at the 2014 Biotech Showcase in San Francisco
PR Newswire - Thu Jan 09, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 2014 Biotech Showcase in San Francisco, California on Tuesday, January 14, 2014 at 11:00 AM Pacific Standard Time (PST). The presentation will take place on the third floor of the Parc 55 Wyndham Hotel.
Courseload Releases Courseload Engage Learning Application for Faculty and Students
PR Newswire - Tue Jan 07, 9:00AM CST
Courseload, an institutional solution for the delivery and use of eTextbooks and digital course materials in higher education, today announced the release of Courseload Engage (Engage), its next generation application designed to enhance engagement and collaboration between students and instructors.
Soligenix Appoints Richard Straube, MD, as Chief Medical Officer
PR Newswire - Mon Jan 06, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has appointed Richard Straube, MD, as its Senior Vice President and Chief Medical Officer. Dr. Straube is a board-certified pediatrician with clinical research experience in host-response modulation. He has had a long and distinguished career of more than 35 years in both academia and industry, most notably with Centocor, Ohmeda Pharmaceuticals, INO Therapeutics, and Stealth Peptides, Inc. Dr. Straube will lead Soligenix's clinical research with primary responsibility for the execution and completion of its multiple clinical programs, including its Phase 2 study in oral mucositis and its Phase 2/3 study in pediatric Crohn's disease.
Dai Telecom and Galooli Announce Cooperation
PR Newswire - Thu Dec 19, 3:00AM CST
Dai Telecom Ltd. and Galooli Ltd. today announced cooperation in the area of remote vehicle telematics. The cooperation centers on the integration of Dai Telecom's Roadstar advanced car phone with Galooli's remote performance monitoring platform - the ZON Control. This solution enables customers to use hands free smart phone capabilities in the car along with advanced remote tracking and fleet management solution, using neither extra hardware nor installation.
Soligenix Inc begins Phase 2 clinical trial of orBec for chronic GI GVHD under USD300,000 NCI grant
M2 - Tue Dec 03, 5:19AM CST
Biopharmaceutical company Soligenix Inc (OTC BB:SNGX) revealed on Monday the launch of a Phase 2, randomised, double-blind, placebo-controlled study evaluating orBec as a treatment for the gastrointestinal (GI) manifestations of chronic Graft-versus-Host disease (GVHD).
Soligenix Announces Initiation of a Phase 2 Clinical Trial of orBec® for the Treatment of Chronic GI GVHD
PR Newswire - Mon Dec 02, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec® (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal (GI) manifestations of chronic Graft-versus-Host disease (GVHD). The study is partially funded by the National Cancer Institute (NCI) which has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 2 clinical trial. The award provides Soligenix with approximately $300,000 over a two-year period.
Soligenix Announces Initial $600,000 Investment and up to $10.6 Million Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC
PR Newswire - Thu Nov 21, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it signed a stock purchase agreement with Lincoln Park Capital Fund, LLC (LPC) providing an initial investment in Soligenix of $600,000 and the availability of additional periodic investments up to $10.0 million over a 36 month term.
Soligenix Reports Third Quarter 2013 Financial Results, and Highlights Recent Accomplishments
PR Newswire - Tue Nov 12, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the quarter and nine months ended September 30, 2013.
Soligenix Submits NIAID Contract Proposal for Development of a Thermostable Ricin Vaccine
PR Newswire - Thu Oct 31, 6:15AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures (MCMs) where there remains an unmet medical need, announced today submission of a full contract proposal to the National Institute of Allergy and Infectious Diseases (NIAID), Division of Microbiology and Infectious Diseases. Successful award of the proposal would support a multi-year, multi-million dollar contract for the advanced development of RiVax(TM) as a vaccine MCM candidate for biodefense threats to protect the public.
Soligenix to Host Conference Call and Webcast Discussion on Oral Mucositis
PR Newswire - Mon Oct 28, 6:15AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet medical need, announced today that Christopher J. Schaber, PhD, President and Chief Executive Officer, Oreola Donini, PhD, Vice President of Preclinical Research and Development, and Stephen T. Sonis, DMD, DMSc, Clinical Professor of Oral Medicine at Harvard School of Dental Medicine, Senior Surgeon and Chief, Divisions of Oral Medicine at Brigham and Women's Hospital and the Dana-Farber Cancer Institute, and Chief Scientific Officer of Biomodels, LLC, as well as Scientific Advisory Board Member and Lead Advisor for the Soligenix Phase 2 clinical study of SGX942 for the treatment of oral mucositis in head and neck cancer, will participate in an expert call and webcast, entitled: Oral Mucositis - Advancing the Next Generation of Therapies.
Soligenix Inc appoints Marco Maria Brughera to board
M2 - Tue Oct 22, 6:05AM CDT
Biopharmaceutical company Soligenix Inc (OTC BB:SNGX) of Marco Maria Brughera, DVM, to its Board of Directors.
